Aprea Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. The 10-K was filed March 26, 2024. Aprea is a clinical-stage oncology company developing synthetic-lethality therapies targeting DNA damage response pathways; it has no approved products and has not generated commercial sales.
Business and pipeline
- ATRN-119: Lead ATR inhibitor in a Phase 1/2a trial for advanced solid tumors with specified DNA damage response mutations. As of February 23, 2024, 16 patients had enrolled across the first five dose cohorts; the first four cohorts were cleared. The filing reports two stable-disease patients and possibly/probably related adverse effects in seven of 15 patients, with no related adverse effects of Grade 4 or higher in the first four cohorts.
- APR-1051: WEE1 inhibitor; the FDA cleared its IND in March 2024, after year-end. A Phase 1 start was anticipated in the first half of 2024.
- The company also has an early-stage program targeting an undisclosed DNA damage response target. It has discontinued active development of its legacy p53-reactivator programs following eprenetapopt’s failed Phase 3 trial.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Grant revenue | $0.58 million | None |
| Research and development expense | $7.63 million | $16.40 million |
| General and administrative expense | $8.43 million | $20.97 million |
| Total operating expenses | $16.06 million | $113.39 million |
| Operating loss | $15.47 million | $113.39 million |
| Net loss | $14.29 million | $112.66 million |
| Net cash used in operating activities | $12.18 million | $25.01 million |
- 2023 net loss per share was $3.95. No meaningful gross margin is reported because the company has no product sales.
- Cash and cash equivalents were $21.61 million at year-end; restricted cash was $0.04 million. Current assets were $22.52 million and current liabilities $4.39 million. Stockholders’ equity was $16.95 million.
- The balance sheet presents no borrowings or debt balance. Cash fell by $7.13 million in 2023; financing activities provided $5.14 million, including net proceeds from a February 2023 share offering and ATM sales.
- Management estimated year-end cash plus approximately $16.0 million gross proceeds from a March 2024 private placement would fund projected operations into the third quarter of 2025. The placement incurred approximately $1.4 million in fees and expenses; potential future cash proceeds from warrants were estimated at approximately $18.0 million.
Changes, outlook, and key risks
- Net loss declined sharply from 2022, primarily because 2022 included a $76.0 million acquired in-process research and development charge from the Atrin acquisition. 2023 R&D and G&A also declined with lower stock-based compensation and the wind-down of legacy programs, partly offset by ATRN-119 trial costs and APR-1051 IND-enabling work.
- Management anticipated ATRN-119 dose escalation completion in the fourth quarter of 2024, Phase 1 readout and recommended Phase 2 dose in the first quarter of 2025, and additional Phase 2a efficacy data in the third quarter of 2025. These are forward-looking estimates, not assured outcomes.
- For APR-1051, management anticipated a clinical-study update in the fourth quarter of 2024, open-label safety/efficacy data in the second quarter of 2025, and a recommended Phase 2 dose in the second half of 2025. These plans depend on trial initiation, enrollment, safety, and funding.
- The company expects continued losses and will need additional financing. Its cash runway estimate depends on assumptions; insufficient funding could force delays, reductions, or discontinuation of programs. Equity financing and warrant exercises may dilute shareholders.
- Material risks include early-stage clinical uncertainty, patient enrollment and trial execution, dependence on third-party manufacturers and CROs, reliance on a single API manufacturer without redundant supply arrangements, competition, intellectual-property challenges, regulatory and reimbursement uncertainty, and cybersecurity exposure. The company reported no material legal proceedings.
- The March 2024 financing included common shares and several warrant tranches; exercise could materially increase shares outstanding. The filing reports 5,430,215 common shares outstanding as of March 26, 2024, compared with 3,736,673 at December 31, 2023.
Investor verification priorities
- Confirm current cash, burn rate, and runway assumptions after the March 2024 financing, including whether further capital is required before the stated runway end.
- Track ATRN-119 enrollment, dose-escalation safety and pharmacokinetics, and whether the reported early disease-control observations persist in larger cohorts.
- Verify APR-1051 trial initiation, enrollment, and emerging safety data against management’s stated timelines.
- Review the financing’s actual net proceeds, warrant terms and exercises, and resulting fully diluted share count.
- Assess manufacturing continuity and clinical supply dependence on third parties, as well as any changes in trial timing, spending, or program priorities.